Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616965 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02616965 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 16 participants.
The verdict
NCT02616965, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase I Trial to assess the feasibility of Romidepsin combined with Brentuximab Vedotin for patients requiring Systemic Therapy for Cutaneous T-cell Lymphoma.
Interventions
- DRUG Brentuximab vedotin
- DRUG Romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2024-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616965
The ClinicalTrials.gov registry entry for NCT02616965 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brentuximab vedotin is the first listed.
NCT02616965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02616965 about?
NCT02616965 is a clinical study titled "A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma". This is a Phase I Trial to assess the feasibility of Romidepsin combined with Brentuximab Vedotin for patients requiring Systemic Therapy for Cutaneous T-cell Lymphoma.
What is the current status of trial NCT02616965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-02-22. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT02616965?
The interventions under investigation include: Brentuximab vedotin (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT02616965?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.